The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an indefinite delivery, indefinite quantity (IDIQ) contract valued up to $25.35 million to VBI Vaccines (Delaware) Inc., doing business as VBI Vaccines Inc., a foreign-owned for-profit corporation. The contract covers the supply of 12 different adult vaccines from July 2024 through June 2025, including vaccines for hepatitis A/B, pneumococcal disease, tetanus/diphtheria, herpes zoster, measles/mumps/rubella, meningococcal disease, HPV, and varicella. These vaccines support CDC's immunization programs administered through state health departments. Additionally, VBI holds Federal Supply Schedule contracts with the Department of Veterans Affairs (VA) to provide drugs, pharmaceuticals, and hematology-related products. Through these IDIQs, VBI can receive task orders from VA medical facilities to supply necessary medications and pharmaceutical supplies for treating veterans.
The original solicitation sought proposals from vaccine manufacturers to establish one or more IDIQ contracts for the purchase of the specified adult vaccines. Key requirements included a minimum 12-month shelf life and federal excise tax amounts per dose. The solicitation outlined estimated maximum and minimum quantities for each vaccine type, but did not provide an overall contract value or budget range. This opportunity was not set-aside and the applicable NAICS code is 325412 - Pharmaceutical Preparation Manufacturing.
Generated 8/29/24, 9:11 AM